Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

被引：13

作者：

Pavoni, Vittorio ^{[1
,2
]}

Gianesello, Lara ^{[3
]}

Horton, Andrew ^{[4
]}

机构：

[1] Santa Maria Annunziata Hosp, Emergency Dept, Florence, Italy

[2] Santa Maria Annunziata Hosp, Anesthesia & Intens Care Unit, Crit Care Area, Florence, Italy

[3] Univ Hosp Careggi, Dept Anesthesia & Intens Care, Orthoped Anesthesia, Largo Palagi 1, I-50139 Florence, Italy

[4] Univ Utah Hlth, Sch Dent, Salt Lake City, UT USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2021年 / 52卷 / 02期

关键词：

COVID-19; Critically ill patients; Venous thromboembolism; Arterial thromboembolism; Antiphospholipid antibodies; Antiphospholipid antibodies syndrome;

D O I：

10.1007/s11239-021-02470-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.

引用

页码：542 / 552

页数：11

共 92 条

[1]

Cui S., Chen S., Li X., Wang F., Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J Thromb Haemost, 18, 6, pp. 1421-1424, (2020)

[2]

Klok F.A., Kruip M., van der Meer N.J.M., Et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, 191, pp. 145-147, (2020)

[3]

Abou-Ismail M.Y., Diamon A., Kapoor S., Arafat Y., Nayak L., The hypercoagulable state in COVID-19: incidence, pathophysiology, and management, Thromb Res, 194, pp. 101-105, (2020)

[4]

Marchandot B., Sattler L., Jesel L., Matsushita K., Schini-Kerth V., Grunebaum L., Morel O., COVID-19 related coagulopathy: a distinct entity?, J Clin Med, 9, 6, (2020)

[5]

Moschonas I.C., Tselepis A.D., SARS-CoV-2 infection and thrombotic complications: a narrative review, J Thromb Thrombol, 15, pp. 1-13, (2021)

[6]

Hasan A.H., Bomze D., Risch L., Et al., Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies, Clin Infect Dis, 2020, 30, (2020)

[7]

Wassernann A., Uber Entwicklung und den gegenwartinggen Stand der Serodiagnostic gegenuber Syphilis, Berl Klin Wochenschr, 44, pp. 1599-1634, (1907)

[8]

Harris E.N., Gharavi A.E., Boey M.L., Patel M.B., Mackworth-Young C.G., Loizou S., Hughes G.R., Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematous, Lancet, 1983, 2, pp. 1211-1214, (1983)

[9]

Cacoub P., Renou C., Rosenthal M.L., Et al., Extrahepatic manifestations associated with hepatitis C infection. A prospective multicentre study of 312 patients, Medicine, 79, pp. 45-56, (2000)

[10]

Yamazaki M., Asakura H., Kawamura Y., Ohka T., Endo M., Matsuda T., Transient lupus anticoagulant induced by Epstein-Barr virus infection, Blood Coagul Fibrinol, 2, pp. 771-774, (1991)

← 1 2 3 4 5 6 7 8 9 10 →